Tuesday, 23 May 2017

Newer antitubercular drugs:

Delamanid (OPC-67683; nitrodihydro imidazooxazole derivative) it inhibits mycolic acid synthesis with a great efficacy against multidrug-resistant strains of M. tuberculosis. No significant adverse events and no cross-resistance have been reported.

Bedaquiline ( Sirturo; Janssen Therapeutics) diarylquinoline for MDR &XDR TB, FDA Approved December 2012, it inhibits ATP synthesis (energy production) by inhibiting ATP synthase. It may produce arrhythmias and cardiac arrest.